Diabetes, Vol 44, Issue 2 216-220, Copyright © 1995 by American Diabetes Association

ARTICLES

Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes

K Daw and AC Powers
Department of Medicine, Vanderbilt University, Nashville, Tennessee 37232.

Although most individuals with insulin-dependent diabetes mellitus (IDDM) have autoantibodies to glutamic acid decarboxylase (GAD), antibodies to GAD are also present in some individuals with a low risk of developing diabetes. The GAD autoantibodies of IDDM are specific for the GAD65 isoform, do not bind denatured GAD protein, and target epitope(s) dependent on conformation of the protein. However, the IDDM epitopes have been difficult to further define because the antibodies do not bind GAD protein fragments or synthetic peptides. Since the GAD67 isoform is highly homologous to GAD65 but is usually not a target of the GAD autoantibodies in IDDM sera, we created six GAD65/GAD67 chimeric proteins to maintain the overall GAD protein conformation and used these chimeric proteins to map conformation-dependent epitopes of GAD65 targeted by IDDM sera. We find that the GAD binding present in most IDDM sera (n = 11 of 12) is composed of two distinct GAD antibody specificities that target different conformation-dependent regions of the GAD65 protein, one that is located between amino acids 240 and 435 (termed IDDM-E1) and one that is located between amino acids 451 and 570 (termed IDDM-E2). One IDDM serum (n = 1 of 12) bound only the IDDM-E1 region. Identification of epitopes targeted by IDDM sera may allow one to distinguish between GAD antibody-positive individuals at high and low risk of developing IDDM and to determine if differences in the autoimmune repertoire directed at GAD are present. The chimeric GAD65/GAD67 proteins may also be useful in designing GAD assays specific for IDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Raju, J. Foote, J. P. Banga, T. R. Hall, C. J. Padoa, M. C. Dalakas, E. Ortqvist, and C. S. Hampe Analysis of GAD65 Autoantibodies in Stiff-Person Syndrome Patients J. Immunol., December 1, 2005; 175(11): 7755 - 7762. [Abstract] [Full Text] [PDF]

				C. J. Padoa, J. P. Banga, A.-M. Madec, M. Ziegler, M. Schlosser, E. Ortqvist, I. Kockum, J. Palmer, O. Rolandsson, K. A. Binder, et al. Recombinant Fabs of Human Monoclonal Antibodies Specific to the Middle Epitope of GAD65 Inhibit Type 1 Diabetes-Specific GAD65Abs Diabetes, November 1, 2003; 52(11): 2689 - 2695. [Abstract] [Full Text] [PDF]

				T. Kobayashi, S. Tanaka, M. Okubo, K. Nakanishi, T. Murase, and A. Lernmark Unique Epitopes of Glutamic Acid Decarboxylase Autoantibodies in Slowly Progressive Type 1 Diabetes J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4768 - 4775. [Abstract] [Full Text] [PDF]

				C. S. Hampe, L. P. Hammerle, L. Bekris, E. Örtqvist, I. Kockum, O. Rolandsson, M. Landin-Olsson, C. Törn, B. Persson, and A. Lernmark Recognition of Glutamic Acid Decarboxylase (GAD) by Autoantibodies from Different GAD Antibody-Positive Phenotypes J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4671 - 4679. [Abstract] [Full Text]

				A. Falorni, G. Gambelunghe, F. Forini, G. Kassi, A. Cosentino, P. Candeloro, G. B. Bolli, P. Brunetti, and F. Calcinaro Autoantibody Recognition of COOH-Terminal Epitopes of GAD65 Marks the Risk for Insulin Requirement in Adult-Onset Diabetes Mellitus J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 309 - 316. [Abstract] [Full Text]

				J. Tremble, N. G. Morgenthaler, A. Vlug, A. C. Powers, M. R. Christie, W. A. Scherbaum, and J. P. Banga Human B Cells Secreting Immunoglobulin G to Glutamic Acid Decarboxylase-65 from a Nondiabetic Patient with Multiple Autoantibodies and Graves' Disease: A Comparison with Those Present in Type 1 Diabetes J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2664 - 2670. [Abstract] [Full Text] [PDF]